$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000165495422006963 Filed on May 16, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$770.7K	$216.1K	$250.0K
YoY Change	339.95%	143.51%	-252.47%
Cost Of Revenue	$87.52K	$46.91K	$29.17K
YoY Change	131.53%	-15.39%	-0.78%
Gross Profit	$683.2K	$169.2K	$220.8K
YoY Change	397.29%	408.06%	-214.2%
Gross Profit Margin	88.64%	78.29%	88.33%
Selling, General & Admin	$6.348M	$3.010M	$3.318M
YoY Change	6.68%	-24.95%	-34.24%
% of Gross Profit	929.15%	1778.8%	1502.41%
Research & Development	$7.436M	$4.980M	$5.426M
YoY Change	113.57%	98.45%	35.27%
% of Gross Profit	1088.4%	2943.5%	2457.28%
Depreciation & Amortization	$42.43K	$44.09K	$27.59K
YoY Change	237.82%	199.73%	165.03%
% of Gross Profit	6.21%	26.06%	12.49%
Operating Expenses	$13.78M	$8.037M	$8.773M
YoY Change	46.14%	22.23%	-3.44%
Operating Profit	-$13.10M	-$7.820M	-$8.451M
YoY Change	40.95%	20.57%	-8.63%
Interest Expense	$333.5K	$3.019K	$2.773K
YoY Change	-244.02%		48.21%
% of Operating Profit
Other Income/Expense, Net		$188.8K	-$235.3K
YoY Change		-75.04%	-68.29%
Pretax Income	-$12.77M	-$7.632M	-$8.686M
YoY Change	-8.37%	33.19%	-13.06%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.77M	-$7.632M	-$8.686M
YoY Change	-8.37%	33.19%	-13.06%
Net Earnings / Revenue	-1656.54%	-3531.56%	-3474.59%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.335M	-$31.96K	-$36.46K
COMMON SHARES
Basic Shares Outstanding	231.8M shares	231.7M shares	231.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.94M	$37.72M	$47.33M
YoY Change	-50.19%	-45.05%	-34.41%
Cash & Equivalents	$29.94M	$37.72M	$47.33M
Short-Term Investments
Other Short-Term Assets	$1.932M	$2.705M	$2.380M
YoY Change	-36.84%	-2.01%	-6.93%
Inventory	$944.5K	$1.032M	$1.079M
Prepaid Expenses
Receivables	$1.780M	$790.0K	$584.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$34.60M	$42.25M	$51.37M
YoY Change	-47.51%	-46.78%	-39.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$539.3K	$544.6K	$511.3K
YoY Change	468.79%	-61.91%	-58.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	0.0%	-0.01%	-0.01%
Total Long-Term Assets	$1.475M	$1.570M	$1.626M
YoY Change	6.13%	5.64%	26.38%
TOTAL ASSETS
Total Short-Term Assets	$34.60M	$42.25M	$51.37M
Total Long-Term Assets	$1.475M	$1.570M	$1.626M
Total Assets	$36.07M	$43.82M	$52.99M
YoY Change	-46.4%	-45.82%	-38.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.158M	$2.403M	$160.2K
YoY Change	392.88%	178.09%	-86.36%
Accrued Expenses	$6.875M	$3.175M	$6.178M
YoY Change	18.59%	-42.73%	21.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.9K	$99.60K	$96.92K
YoY Change
Total Short-Term Liabilities	$16.26M	$11.98M	$13.86M
YoY Change	54.68%	19.33%	91.24%
LONG-TERM LIABILITIES
Long-Term Debt	$152.4K	$178.1K	$204.9K
YoY Change
Other Long-Term Liabilities	$2.861M	$2.955M	$3.014M
YoY Change	-54.09%	-62.87%	-74.23%
Total Long-Term Liabilities	$2.861M	$2.955M	$3.014M
YoY Change	-54.09%	-62.87%	-74.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.26M	$11.98M	$13.86M
Total Long-Term Liabilities	$2.861M	$2.955M	$3.014M
Total Liabilities	$19.80M	$15.73M	$17.80M
YoY Change	12.23%	-12.58%	-6.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$388.0M	-$375.2M	-$367.6M
YoY Change	10.29%
Common Stock	$92.71K	$2.318M	$2.317M
YoY Change	-95.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.27M	$28.09M	$35.20M
YoY Change
Total Liabilities & Shareholders Equity	$36.07M	$43.82M	$52.99M
YoY Change	-46.4%	-45.82%	-38.93%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$12.77M	-$7.632M	-$8.686M
YoY Change	-8.37%	33.19%	-13.06%
Depreciation, Depletion And Amortization	$42.43K	$44.09K	$27.59K
YoY Change	237.82%	199.73%	165.03%
Cash From Operating Activities	-$7.719M	-$9.491M	-$6.289M
YoY Change	-9.58%	170.84%	-56.39%
INVESTING ACTIVITIES
Capital Expenditures	-$37.11K	-$77.40K	-$89.10K
YoY Change		1253.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$37.11K	-$77.40K	-$89.10K
YoY Change		1253.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-24.41K	-37.13K	282.3K
YoY Change		705.42%	-2606.66%
NET CHANGE
Cash From Operating Activities	-7.719M	-9.491M	-6.289M
Cash From Investing Activities	-37.11K	-77.40K	-89.10K
Cash From Financing Activities	-24.41K	-37.13K	282.3K
Net Change In Cash	-7.780M	-9.606M	-6.096M
YoY Change	-8.86%	173.3%	-57.76%
FREE CASH FLOW
Cash From Operating Activities	-$7.719M	-$9.491M	-$6.289M
Capital Expenditures	-$37.11K	-$77.40K	-$89.10K
Free Cash Flow	-$7.682M	-$9.414M	-$6.200M
YoY Change	-10.01%	169.07%	-57.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	231773670	shares
CY2022Q1	us-gaap	Inventory Net InventoryNet	1031988	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	1162000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2704886	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3059679	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	42246410	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	65907041	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	544622	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94817	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	968957	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1237813	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	USD
CY2022Q1	us-gaap	Assets Assets	43816905	USD
CY2021Q2	us-gaap	Assets Assets	67296587	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2402739	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	640650	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3175414	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5797378	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	367478	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	351853	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	99602	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5931414	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11976647	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10511788	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	621660	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	900520	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	178139	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2955000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6232907	USD
CY2022Q1	us-gaap	Liabilities Liabilities	15731446	USD
CY2021Q2	us-gaap	Liabilities Liabilities	17645215	USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	40	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231773670	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	230049691	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	2317737	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2300497	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400993760	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399146232	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375226078	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-351795397	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	28085459	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43816905	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67296587	USD
CY2022Q1	ptn	Product Revenue Net ProductRevenueNet	216097	USD
CY2021Q1	ptn	Product Revenue Net ProductRevenueNet	88741	USD
	ptn	Product Revenue Net ProductRevenueNet	447719	USD
	ptn	Product Revenue Net ProductRevenueNet	-363790	USD
CY2022Q1	ptn	License And Contract LicenseAndContract	0	USD
CY2021Q1	ptn	License And Contract LicenseAndContract	0	USD
	ptn	License And Contract LicenseAndContract	250000	USD
	ptn	License And Contract LicenseAndContract	0	USD
CY2022Q1	us-gaap	Revenues Revenues	216097	USD
CY2021Q1	us-gaap	Revenues Revenues	88741	USD
	us-gaap	Revenues Revenues	697719	USD
	us-gaap	Revenues Revenues	-363790	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46908	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55440	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	130012	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	110040	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4980074	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2509490	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13891235	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9444759	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3009528	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4010055	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10163830	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11386574	USD
CY2022Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2021Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	1623795	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8036510	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	6574985	USD
	us-gaap	Operating Expenses OperatingExpenses	24185077	USD
	us-gaap	Operating Expenses OperatingExpenses	19317578	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7820413	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6486244	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23487358	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19681368	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1127	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2834	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4100	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	19769	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	190719	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	753750	USD
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	64000	USD
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	8748	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	3019	USD
	us-gaap	Interest Expense InterestExpense	11423	USD
	us-gaap	Interest Expense InterestExpense	9360	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	188827	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	756584	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	56677	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19157	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7631586	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5729660	USD
CY2022Q1	ptn	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.03
CY2021Q1	ptn	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.02
	ptn	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.10
	ptn	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.08
CY2022Q1	ptn	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	238805370	shares
CY2021Q1	ptn	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	236832283	shares
	ptn	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	238444206	shares
	ptn	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	236525514	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35196307	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	533779	USD
CY2022Q1	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-13041	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7631586	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	28085459	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	8748	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1789947	USD
	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-221311	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1789947	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2459162	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	790438	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1869120	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	280000	USD
	ptn	Option Exercises Amount OptionExercisesAmount	16132	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23430681	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	354793	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2022026	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	130012	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-296923	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1762089	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	148340	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2621964	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1338	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-263235	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	64000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	28085459	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	67835126	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	775305	USD
CY2021Q1	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-4609	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5729660	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	62876162	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	80172849	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2459162	USD
	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-93638	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19662211	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	62876162	USD
	us-gaap	Profit Loss ProfitLoss	23430681	USD
	us-gaap	Profit Loss ProfitLoss	19662211	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	84244	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38561	USD
	ptn	Gain On Termination Agreement GainOnTerminationAgreement	0	USD
	ptn	Gain On Termination Agreement GainOnTerminationAgreement	14676205	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	268856	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	240580	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-229661	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1004400	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7584420	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22203901	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14111599	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	224258	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5721	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-224258	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5721	USD
	ptn	Payment Of Withholding Taxes Related To Restricted PaymentOfWithholdingTaxesRelatedToRestricted	221311	USD
	ptn	Payment Of Withholding Taxes Related To Restricted PaymentOfWithholdingTaxesRelatedToRestricted	93638	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32050	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	280000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16132	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42771	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-93638	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22385388	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-14210958	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82852270	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37719531	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68641312	USD
	us-gaap	Interest Paid Net InterestPaidNet	11423	USD
	us-gaap	Interest Paid Net InterestPaidNet	9360	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23430681	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong> (2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and nine months ended March 31, 2022 may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021, filed with the U.S. Securities and Exchange Commission (“SEC”), which includes consolidated financial statements as of June 30, 2021 and 2020 and for the fiscal years then ended.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2588210	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2503966	USD
CY2022Q1	ptn	Additional Property And Equipment AdditionalPropertyAndEquipment	309791	USD
	ptn	Description Of Finance Lease DescriptionOfFinanceLease	lease obligations for two new finance leases, each with a term of three years
	ptn	Accrued Expenses AccruedExpenses	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Accrued Expenses –</em> Third parties perform a significant portion of the Company’s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27694397	shares
CY2020Q3	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	12000000	USD
CY2021Q1	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	4300000	USD
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	18194000	USD
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	2300000	USD
CY2020Q3	ptn	Inventory And Prepaid Expenses Estimated Fair Value InventoryAndPrepaidExpensesEstimatedFairValue	5817795	USD
CY2020Q3	ptn	Gain On License Termination Agreement GainOnLicenseTerminationAgreement	1623795	USD
CY2021Q2	us-gaap	Loss On Contract Termination LossOnContractTermination	4407987	USD
CY2021Q2	ptn	Net Loss NetLoss	2784192	USD
	ptn	Agreement With Fosun AgreementWithFosun	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Development Co. Ltd. (“Fosun”) for exclusive rights to commercialize Vyleesi in China (the “Fosun License Agreement”). Under the terms of the agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense. Under the Fosun License Agreement, the Company is entitled to receive a $7,500,000 milestone payment when regulatory approval in China is obtained, provided that a commercial supply agreement for Vyleesi has been entered into. Palatin has the potential to receive up to $92,500,000 in additional sales related milestone payments and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun. For the nine months ended March 31, 2022, the Company recorded $250,000 of license and contract revenue from the Fosun License Agreement. </p>
CY2017Q4	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	USD
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	USD
CY2017Q4	ptn	Taxexpenses taxexpenses	500000	USD
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	92500000	USD
	ptn	License And Contract Revenue LicenseAndContractRevenue	250000	USD
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	USD
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	USD
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	USD
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	37500000	USD
CY2022Q1	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	1037350	USD
CY2021Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	454750	USD
CY2022Q1	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	39864	USD
CY2021Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	259468	USD
CY2022Q1	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	815750	USD
CY2021Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	1200000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	811922	USD
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1145461	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2704886	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3059679	USD
CY2022Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37651838	USD
CY2021Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	59730428	USD
CY2022Q1	ptn	Clinical Study Costs ClinicalStudyCosts	1338025	USD
CY2021Q2	ptn	Clinical Study Costs ClinicalStudyCosts	778705	USD
CY2022Q1	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	759308	USD
CY2021Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	569370	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	47797	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	84094	USD
CY2022Q1	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	0	USD
CY2021Q2	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	2340000	USD
CY2022Q1	ptn	Accrued Selling Expenses AccruedSellingExpenses	910545	USD
CY2021Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	1839724	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119739	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	185485	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3175414	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5797378	USD
CY2022Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	9832614	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5931414	USD
CY2022Q1	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	2995000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	USD
CY2021Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	6232907	USD
CY2022Q1	ptn	Company Received CompanyReceived	280000	USD
CY2022Q1	ptn	Common Stock Share Issued CommonStockShareIssued	350000	shares
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	329146	USD
CY2021Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	453439	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21882500	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y2M12D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1034273	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	197650	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	240528	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.69
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	43600	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	103349	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.81
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21692673	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	237370	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	14155952	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.75
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	236358	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7536721	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue	1012	USD
CY2020Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	332785	USD
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	204633	USD
CY2021Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	321866	USD
CY2022Q1	ptn	Vesting Of Restricted Share VestingOfRestrictedShare	32603	shares
CY2022Q1	ptn	Aggregate Value AggregateValue	13041	USD

Files In Submission

Name	View Source	Status
0001654954-22-006963-index-headers.html	Edgar Link	pending
0001654954-22-006963-index.html	Edgar Link	pending
0001654954-22-006963.txt	Edgar Link	pending
0001654954-22-006963-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20220331.xsd	Edgar Link	pending
ptn-20220331_cal.xml	Edgar Link	unprocessable
ptn-20220331_def.xml	Edgar Link	unprocessable
ptn-20220331_lab.xml	Edgar Link	unprocessable
ptn-20220331_pre.xml	Edgar Link	unprocessable
ptn_10q.htm	Edgar Link	pending
ptn_10qimg10.jpg	Edgar Link	pending
ptn_10qimg11.jpg	Edgar Link	pending
ptn_10q_htm.xml	Edgar Link	completed
ptn_ex101.htm	Edgar Link	pending
ptn_ex102.htm	Edgar Link	pending
ptn_ex103.htm	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
ptn_ex33.htm	Edgar Link	pending
ptn_ex34.htm	Edgar Link	pending
ptn_ex35.htm	Edgar Link	pending
ptn_ex36.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q2 Form 10-Q Financial Statement

#000165495422006963 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q2 Form 10-Q Financial Statement

#000165495422006963 Filed on May 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn